{
    "id": 3074,
    "fullName": "FGFR3 G370C",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "FGFR3 G370C lies within the juxtamembrane region of the Fgfr3 protein (PMID: 12009017). G370C confers a gain of function to the Fgfr3 protein, resulting in increased Fgfr3 phosphorylation compared to wild-type and constitutive activation of the mitogen activated protein kinase (MAPK) signaling pathway (PMID: 12009017).",
            "references": [
                {
                    "id": 1806,
                    "pubMedId": 12009017,
                    "title": "Differential activation of cysteine-substitution mutants of fibroblast growth factor receptor 3 is determined by cysteine localization.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/12009017"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 2261,
        "geneSymbol": "FGFR3",
        "terms": [
            "FGFR3",
            "ACH",
            "CD333",
            "CEK2",
            "HSFGFR3EX",
            "JTK4"
        ]
    },
    "variant": "G370C",
    "createDate": "02/11/2015",
    "updateDate": "10/05/2018",
    "referenceTranscriptCoordinates": {
        "id": 116793,
        "transcript": "NM_000142",
        "gDna": "chr4:g.1804362G>T",
        "cDna": "c.1108G>T",
        "protein": "p.G370C",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 17672,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (BCL2001) that supported FDA approval, Balversa (erdafitinib) treatment resulted in an objective response rate of 40% (40/99, 3 complete response, 37 partial response) and a disease control rate of 80% in patients with metastatic or unresectable urothelial carcinoma harboring FGFR alterations and FGFR3 G370C is included in the companion diagnostic (PMID: 31340094; NCT02365597).",
            "molecularProfile": {
                "id": 2897,
                "profileName": "FGFR3 G370C"
            },
            "therapy": {
                "id": 1028,
                "therapyName": "Erdafitinib",
                "synonyms": null
            },
            "indication": {
                "id": 4006,
                "name": "bladder urothelial carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15450,
                    "pubMedId": null,
                    "title": "Balversa (erdafitinib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212018"
                },
                {
                    "id": 15824,
                    "pubMedId": 31340094,
                    "title": "Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31340094"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17154,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (BCL2001) that supported FDA approval, Balversa (erdafitinib) treatment resulted in an objective response rate of 40% (40/99, 3 complete response, 37 partial response) and a disease control rate of 80% in patients with metastatic or unresectable urothelial carcinoma harboring FGFR alterations and FGFR3 G370C is included in the companion diagnostic (PMID: 31340094; NCT02365597).",
            "molecularProfile": {
                "id": 2897,
                "profileName": "FGFR3 G370C"
            },
            "therapy": {
                "id": 1028,
                "therapyName": "Erdafitinib",
                "synonyms": null
            },
            "indication": {
                "id": 2671,
                "name": "transitional cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15450,
                    "pubMedId": null,
                    "title": "Balversa (erdafitinib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212018"
                },
                {
                    "id": 15824,
                    "pubMedId": 31340094,
                    "title": "Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31340094"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        }
    ],
    "molecularProfiles": [
        {
            "id": 2897,
            "profileName": "FGFR3 G370C",
            "profileTreatmentApproaches": [
                {
                    "id": 7541,
                    "name": "FGFR3 Inhibitor",
                    "profileName": "FGFR3 G370C"
                },
                {
                    "id": 7540,
                    "name": "FGFR Inhibitor (Pan)",
                    "profileName": "FGFR3 G370C"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 116792,
            "transcript": "XM_006713873",
            "gDna": "chr4:g.1804362G>T",
            "cDna": "c.1108G>T",
            "protein": "p.G370C",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 116789,
            "transcript": "XM_011513420",
            "gDna": "chr4:g.1804362G>T",
            "cDna": "c.1108G>T",
            "protein": "p.G370C",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 116790,
            "transcript": "XM_011513422",
            "gDna": "chr4:g.1804362G>T",
            "cDna": "c.1108G>T",
            "protein": "p.G370C",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 116793,
            "transcript": "NM_000142",
            "gDna": "chr4:g.1804362G>T",
            "cDna": "c.1108G>T",
            "protein": "p.G370C",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 116791,
            "transcript": "XM_006713872",
            "gDna": "chr4:g.1804362G>T",
            "cDna": "c.1108G>T",
            "protein": "p.G370C",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}